MNMD Key Statistics, Chart & Performance
The current stock price of MNMD is 12.06 USD. In the past month the price decreased by -1.87%. In the past year, price increased by 62.1%.
MNMD Latest News, Press Relases and Analysis
MNMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About MNMD
Company Profile
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2015-05-04. The firm is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Company Info
MIND MEDICINE MINDMED INC
One World Trade Center, Suite 8500
New York City NEW YORK US
Employees: 74
Phone: 12122206633
MIND MEDICINE MINDMED INC / MNMD FAQ
Can you describe the business of MIND MEDICINE MINDMED INC?
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2015-05-04. The firm is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Can you provide the latest stock price for MIND MEDICINE MINDMED INC?
The current stock price of MNMD is 12.06 USD. The price decreased by -1.63% in the last trading session.
Does MIND MEDICINE MINDMED INC pay dividends?
MNMD does not pay a dividend.
What is the ChartMill rating of MIND MEDICINE MINDMED INC stock?
MNMD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does MIND MEDICINE MINDMED INC belong to?
MIND MEDICINE MINDMED INC (MNMD) operates in the Health Care sector and the Pharmaceuticals industry.
Is MIND MEDICINE MINDMED INC (MNMD) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MNMD.
What is MIND MEDICINE MINDMED INC worth?
MIND MEDICINE MINDMED INC (MNMD) has a market capitalization of 1.19B USD. This makes MNMD a Small Cap stock.
MNMD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MNMD. When comparing the yearly performance of all stocks, MNMD is one of the better performing stocks in the market, outperforming 93.4% of all stocks.
MNMD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MNMD. While MNMD seems to be doing ok healthwise, there are quite some concerns on its profitability.
MNMD Financial Highlights
Over the last trailing twelve months MNMD reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS increased by 13.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.95% | ||
| ROE | -128.72% | ||
| Debt/Equity | 0.31 |
MNMD Forecast & Estimates
18 analysts have analysed MNMD and the average price target is 26.15 USD. This implies a price increase of 116.83% is expected in the next year compared to the current price of 12.06.